HDAC9 and cancer: Histone deacetylase (HDAC) inhibitors (HDACis) are a successful example of epigenetic therapy, with 5 inhibitors currently approved by the US Food and Drug Administration for treatment of different hematological malignancies and a growing number of agents currently in different stages of clinical testing for a variety of cancers (1).